440 related articles for article (PubMed ID: 19371316)
21. Associations between CYP2B6 polymorphisms and pharmacokinetics after a single dose of nevirapine or efavirenz in African americans.
Haas DW; Gebretsadik T; Mayo G; Menon UN; Acosta EP; Shintani A; Floyd M; Stein CM; Wilkinson GR
J Infect Dis; 2009 Mar; 199(6):872-80. PubMed ID: 19239339
[TBL] [Abstract][Full Text] [Related]
22. Effect of CYP2B6 Gene Polymorphisms on Efavirenz Plasma Concentrations in Chinese Patients with HIV Infection.
Meng X; Yin K; Wang J; Dong P; Liu L; Shen Y; Shen L; Ma Q; Lu H; Cai W
PLoS One; 2015; 10(6):e0130583. PubMed ID: 26107645
[TBL] [Abstract][Full Text] [Related]
23. Dosage Optimization of Efavirenz Based on a Population Pharmacokinetic-Pharmacogenetic Model of HIV-infected Patients in Thailand.
Chaivichacharn P; Avihingsanon A; Manosuthi W; Ubolyam S; Tongkobpetch S; Shotelersuk V; Punyawudho B
Clin Ther; 2020 Jul; 42(7):1234-1245. PubMed ID: 32451120
[TBL] [Abstract][Full Text] [Related]
24. Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens.
Wyen C; Hendra H; Siccardi M; Platten M; Jaeger H; Harrer T; Esser S; Bogner JR; Brockmeyer NH; Bieniek B; Rockstroh J; Hoffmann C; Stoehr A; Michalik C; Dlugay V; Jetter A; Knechten H; Klinker H; Skaletz-Rorowski A; Fätkenheuer G; Egan D; Back DJ; Owen A;
J Antimicrob Chemother; 2011 Sep; 66(9):2092-8. PubMed ID: 21715435
[TBL] [Abstract][Full Text] [Related]
25. Breast milk pharmacokinetics of efavirenz and breastfed infants' exposure in genetically defined subgroups of mother-infant pairs: an observational study.
Olagunju A; Bolaji O; Amara A; Waitt C; Else L; Adejuyigbe E; Siccardi M; Back D; Khoo S; Owen A
Clin Infect Dis; 2015 Aug; 61(3):453-63. PubMed ID: 25882300
[TBL] [Abstract][Full Text] [Related]
26. CYP2B6 G516T polymorphism but not rifampin coadministration influences steady-state pharmacokinetics of efavirenz in human immunodeficiency virus-infected patients in South India.
Ramachandran G; Hemanth Kumar AK; Rajasekaran S; Kumar P; Ramesh K; Anitha S; Narendran G; Menon P; Gomathi C; Swaminathan S
Antimicrob Agents Chemother; 2009 Mar; 53(3):863-8. PubMed ID: 19124658
[TBL] [Abstract][Full Text] [Related]
27. The relationships of ABCB1 3435C>T and CYP2B6 516G>T with high-density lipoprotein cholesterol in HIV-infected patients receiving Efavirenz.
Mahungu TW; Nair D; Smith CJ; Egan D; Youle M; Johnson MA; Khoo SH; Back DJ; Owen A
Clin Pharmacol Ther; 2009 Aug; 86(2):204-11. PubMed ID: 19474786
[TBL] [Abstract][Full Text] [Related]
28. Correlation of CYP2B6-516G > T Polymorphism with Plasma Efavirenz Concentration and Depression in HIV-Infected Adults in Northern Thailand.
Aurpibul L; Chotirosniramit N; Sugandhavesa P; Kosashunhanan N; Thetket S; Supindham T; Piyamongkol W; Supparatpinyo K
Curr HIV Res; 2012 Dec; 10(8):653-60. PubMed ID: 22950382
[TBL] [Abstract][Full Text] [Related]
29. Mid-dosing interval efavirenz plasma concentrations in HIV-1-infected children in Rwanda: treatment efficacy, tolerability, adherence, and the influence of CYP2B6 polymorphisms.
Mutwa PR; Fillekes Q; Malgaz M; Tuyishimire D; Kraats Rv; Boer KR; Burger DM; van Schaik RH; Muganga N; Geelen SP
J Acquir Immune Defic Syndr; 2012 Aug; 60(4):400-4. PubMed ID: 22481606
[TBL] [Abstract][Full Text] [Related]
30. Haplotype structure of CYP2B6 and association with plasma efavirenz concentrations in a Chilean HIV cohort.
Carr DF; la Porte CJ; Pirmohamed M; Owen A; Cortes CP
J Antimicrob Chemother; 2010 Sep; 65(9):1889-93. PubMed ID: 20639527
[TBL] [Abstract][Full Text] [Related]
31. A single-nucleotide polymorphism in CYP2B6 leads to >3-fold increases in efavirenz concentrations in plasma and hair among HIV-infected women.
Gandhi M; Greenblatt RM; Bacchetti P; Jin C; Huang Y; Anastos K; Cohen M; Dehovitz JA; Sharp GB; Gange SJ; Liu C; Hanson SC; Aouizerat B;
J Infect Dis; 2012 Nov; 206(9):1453-61. PubMed ID: 22927450
[TBL] [Abstract][Full Text] [Related]
32. CYP2B6 Haplotype Predicts Efavirenz Plasma Concentration in Black South African HIV-1-Infected Children: A Longitudinal Pediatric Pharmacogenomic Study.
Reay R; Dandara C; Viljoen M; Rheeders M
OMICS; 2017 Aug; 21(8):465-473. PubMed ID: 28816644
[TBL] [Abstract][Full Text] [Related]
33. Tribal ethnicity and CYP2B6 genetics in Ugandan and Zimbabwean populations in the UK: implications for efavirenz dosing in HIV infection.
Jamshidi Y; Moreton M; McKeown DA; Andrews S; Nithiyananthan T; Tinworth L; Holt DW; Sadiq ST
J Antimicrob Chemother; 2010 Dec; 65(12):2614-9. PubMed ID: 20952418
[TBL] [Abstract][Full Text] [Related]
34. Therapeutic drug monitoring and pharmacogenetic study of HIV-infected ethnic Chinese receiving efavirenz-containing antiretroviral therapy with or without rifampicin-based anti-tuberculous therapy.
Lee KY; Lin SW; Sun HY; Kuo CH; Tsai MS; Wu BR; Tang SY; Liu WC; Chang SY; Hung CC
PLoS One; 2014; 9(2):e88497. PubMed ID: 24551111
[TBL] [Abstract][Full Text] [Related]
35. The role of genetic polymorphisms in cytochrome P450 and effects of tuberculosis co-treatment on the predictive value of CYP2B6 SNPs and on efavirenz plasma levels in adult HIV patients.
Bienvenu E; Swart M; Dandara C; Ashton M
Antiviral Res; 2014 Feb; 102():44-53. PubMed ID: 24316028
[TBL] [Abstract][Full Text] [Related]
36. Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6 *6 and *26.
Gatanaga H; Hayashida T; Tsuchiya K; Yoshino M; Kuwahara T; Tsukada H; Fujimoto K; Sato I; Ueda M; Horiba M; Hamaguchi M; Yamamoto M; Takata N; Kimura A; Koike T; Gejyo F; Matsushita S; Shirasaka T; Kimura S; Oka S
Clin Infect Dis; 2007 Nov; 45(9):1230-7. PubMed ID: 17918089
[TBL] [Abstract][Full Text] [Related]
37. Influence of the cytochrome P450 2B6 genotype on population pharmacokinetics of efavirenz in human immunodeficiency virus patients.
Cabrera SE; Santos D; Valverde MP; Domínguez-Gil A; González F; Luna G; García MJ
Antimicrob Agents Chemother; 2009 Jul; 53(7):2791-8. PubMed ID: 19433561
[TBL] [Abstract][Full Text] [Related]
38. Influence of host genetic factors on efavirenz plasma and intracellular pharmacokinetics in HIV-1-infected patients.
Elens L; Vandercam B; Yombi JC; Lison D; Wallemacq P; Haufroid V
Pharmacogenomics; 2010 Sep; 11(9):1223-34. PubMed ID: 20860463
[TBL] [Abstract][Full Text] [Related]
39. Importance of ethnicity, CYP2B6 and ABCB1 genotype for efavirenz pharmacokinetics and treatment outcomes: a parallel-group prospective cohort study in two sub-Saharan Africa populations.
Ngaimisi E; Habtewold A; Minzi O; Makonnen E; Mugusi S; Amogne W; Yimer G; Riedel KD; Janabi M; Aderaye G; Mugusi F; Bertilsson L; Aklillu E; Burhenne J
PLoS One; 2013; 8(7):e67946. PubMed ID: 23861838
[TBL] [Abstract][Full Text] [Related]
40. Efavirenz dosing: influence of drug metabolizing enzyme polymorphisms and concurrent tuberculosis treatment.
Gengiah TN; Botha JH; Yende-Zuma N; Naidoo K; Abdool Karim SS
Antivir Ther; 2015; 20(3):297-306. PubMed ID: 25318122
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
